Læknaneminn - 01.04.1998, Blaðsíða 94

Maríanna Garðarsclóttir
10. Kay MA, Woo SLC. Gene therapy for metabolic disorders. Trends
in Genetics 1994; 7:253-7.
11. Larson SM, Tjuvajev J, Blasberg R. Triumph over mischance: A
role for nuclear medicine in gene therapy. J Nucl Med 1997;
38:1230-3.
12. Hall SJ, Chen S, Woo SLC. Gene Therapy ‘97. The promise and
reality of cancer gene therapy. Am. J. Hum. Genet. 1997; 61:785-
9.
13. Culver KW, Blease RM. Gene therapy for cancer. Trends in Genetics
1994; 5:174-8.
14. Sadelain M, Luzatto L. Immuno gene therapy comes into its own.
GeneTherapy 1997; 4:1120-31.
15. Gilboa E, Smith C. Gene therapy for infectious diseases: the AIDS
model. Trends in Genetics 1994; 4:139-44.
16. Esparza J, Osmanov S, Heyward WL. HIV preventive vaccines.
Progress to date. Drugs 1995; 50:792-804.
17. Lu S. Developing DNA vaccines against immunodeficiency viruses.
CurrTop Microbiol Immunol 1998; 226:161-73.
18. Wang B, Dang K, Agadjanyan MG. Mucosal immunization with a
DNA vaccine induces immune responses against HIV-1 at a mucos-
al site. Vaccine 1997; 15:821-5.
19. Boyer JD, Ugen KE, Wang B. Protection of chimpanzees from
high-dose heterologous HIV-1 challenge by DNA vaccination.
Nat Med 1997; 3:526-32.
20. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D,
Wong-Staal E A hairpin ribozyme inhibits expression of diverse
strains of human immunodeficiency virus type 1. Proc
Natl Acad Sci U S A 1993; 90:6340-4
92
LÆKNANEMINN
1. tbl. 1998, 51. árg.